Pascal Deschatelets - 08 Mar 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
08 Mar 2024
Net transactions value
-$4,043,926
Form type
4
Filing time
11 Mar 2024, 16:08:32 UTC
Previous filing
13 Feb 2024
Next filing
09 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $253,623 +69,107 +6.2% $3.67* 1,185,090 08 Mar 2024 Direct F1
transaction APLS Common Stock Sale $2,645,173 -42,750 -3.6% $61.88 1,142,340 08 Mar 2024 Direct F2, F3
transaction APLS Common Stock Sale $1,646,041 -26,257 -2.3% $62.69 1,116,083 08 Mar 2024 Direct F4, F5
transaction APLS Common Stock Sale $6,335 -100 -0.01% $63.35 1,115,983 08 Mar 2024 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -69,107 -39% $0.000000 106,387 08 Mar 2024 Common Stock 69,107 $3.76 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
F2 This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
F3 This transaction was executed in multiple trades at prices ranging from $61.30 - $62.295. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
F5 This transaction was executed in multiple trades at prices ranging from $62.30 - $63.2925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
F7 This stock option was granted on 02/08/2016 and is fully vested.